Camrelizumab: all 354 studies that test it
Page 2 of 4. Open to participants first (126), then studies with results posted, then the rest; newest registration first within each.
- Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)RecruitingNCT04932187Phase 1
- Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT04907344Phase 2/3
- HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal MetastasisNot yet recruitingNCT04889768Not applicable
- A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary MetastasisNot yet recruitingNCT04888806Phase 2
- Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT04861467Phase 2
- Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCCRecruitingNCT04826679Phase 2
- Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined ChemotherapyRecruitingNCT04812002Phase 2
- A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBCRecruitingNCT04803539Phase 2/3
- Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal CarcinomaRecruitingNCT04782765Phase 2
- Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric CancerRecruitingNCT04781686Phase 2
- Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLCRecruitingNCT04530227Phase 2
- The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.RecruitingNCT04514081Phase 2
- Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung CancerNot yet recruitingNCT04506242Phase 2
- A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative BreastRecruitingNCT04481763Phase 1/2
- Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II StudyRecruitingNCT04454905Phase 2
- Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal CarcinomaRecruitingNCT04453826Phase 3
- A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck CancerNot yet recruitingNCT04405154Phase 2
- Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJCRecruitingNCT04342910Phase 3
- Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral MelanomaRecruitingNCT04331093Phase 2
- Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical CarcinomaRecruitingNCT04318730Phase 2
- Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic CholangiocarcinomaRecruitingNCT04299581Phase 2
- Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin LymphomaRecruitingNCT04233294Phase 2
- Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal CarcinomaRecruitingNCT04221516Phase 2
- Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal CarcinomaRecruitingNCT04143984Phase 2
- MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue SarcomaRecruitingNCT04074564Early Phase 1
- Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT04070040Phase 2
- Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell CarcinomaCompletedNCT04649476Phase 2Results posted
- Neoadjuvant Therapy for Locally Advanced Colon CancerCompletedNCT04625803Phase 2Results posted
- A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Phase 3Results posted
- A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue SarcomaTerminatedNCT03711279Phase 2Results posted
- SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.CompletedNCT03558191Phase 2Results posted
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)CompletedNCT03463876Phase 2Results posted
- SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard TherapyCompletedNCT03417895Phase 2Results posted
- PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's LymphomaCompletedNCT03155425Phase 2Results posted
- Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal CancerCompletedNCT03099382Phase 3Results posted
- A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)CompletedNCT03083041Phase 2Results posted
- A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Phase 2Results posted
- Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and EfficacyActive, not recruitingNCT07471815Phase 2
- Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)SuspendedNCT07057089Phase 2
- SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARCStatus unknownNCT06516445Phase 2
- Neoadjuvant Immunotherapy for T4 dMMR Colon CancerActive, not recruitingNCT06215677Phase 2
- A SHR-1210 BE Study on Healthy SubjectsTerminatedNCT05799183Phase 1
- CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPCStatus unknownNCT05724355Phase 2
- Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic CholangiocarcinomaStatus unknownNCT05697237Not applicable
- Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC PatientsCompletedNCT05673577Phase 2
- Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast CancerSuspendedNCT05656131Phase 2
- Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma PatientsStatus unknownNCT05611463Phase 2
- Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm StudyActive, not recruitingNCT05602935Phase 2
- A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell CarcinomaStatus unknownNCT05600998Not applicable
- A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ TrastuzumabStatus unknownNCT05583383Not applicable
- Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder CancerStatus unknownNCT05564897Phase 2
- SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05524168Phase 2
- Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT05476380Phase 2
- Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung CancerStatus unknownNCT05472467Phase 2
- Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract CancerActive, not recruitingNCT05451290Phase 2
- Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical StudyStatus unknownNCT05441254Phase 2
- Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric CancerStatus unknownNCT05342389Phase 2
- A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural EffusionStatus unknownNCT05330065Phase 1/2
- Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ LymphomaStatus unknownNCT05320081Phase 2
- An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced GastrointestinalStatus unknownNCT05225844Phase 2
- A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of PatientsStatus unknownNCT05214976Phase 2
- The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCCCompletedNCT05213884Phase 2
- Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal CancerStatus unknownNCT05193292Phase 2
- Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.Active, not recruitingNCT05176002Phase 1/2
- Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCCStatus unknownNCT05171309Phase 2
- A Study of Carilizumab Combined With Concurrent ChemoradiotherapyStatus unknownNCT05151549Phase 2
- Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine CarcinomasStatus unknownNCT05142865Phase 2
- HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE FailureStatus unknownNCT05135364Phase 2
- Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal SinusesStatus unknownNCT05114707Phase 2
- Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaStatus unknownNCT05111444Phase 2
- A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLCTerminatedNCT05106335Phase 3
- A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric CancerSuspendedNCT05101616Phase 1/2
- A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular CarcinomaCompletedNCT05099848Phase 2
- Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of ChemotherapyStatus unknownNCT05097248Phase 2
- Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric CancerStatus unknownNCT05095636Phase 2
- Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCLStatus unknownNCT05093140Phase 2
- Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast CancerStatus unknownNCT05088057Phase 2
- Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast CancerStatus unknownNCT05085626Phase 2
- Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric CancerStatus unknownNCT05070598Phase 2
- To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced MelanomaStatus unknownNCT05051865Phase 2
- DCF Combined With Camrelizumab in the Treatment of Esophageal CancerStatus unknownNCT05050760Not applicable
- Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.Active, not recruitingNCT05043688Phase 3
- Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal CancerStatus unknownNCT05019534Phase 1
- A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.Status unknownNCT05005468Phase 2
- Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular CarcinomaCompletedNCT05003700Phase 2
- Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLCStatus unknownNCT05001412Phase 1
- Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 BlockadeStatus unknownNCT04984018Phase 2
- Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of MelanomaStatus unknownNCT04979585Phase 2
- First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical CancerTerminatedNCT04974944Phase 2
- A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical CancerStatus unknownNCT04974827Phase 2
- Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC TreatmentStatus unknownNCT04970043Not applicable
- Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)TerminatedNCT04952571Phase 2
- A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLCStatus unknownNCT04950400Not applicable
- Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric AdenocarcinomaStatus unknownNCT04948125Phase 2
- Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLCStatus unknownNCT04943029Phase 2
- The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04937673Phase 2
- Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal CancerStatus unknownNCT04929652Phase 1/2
- Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue SarcomaStatus unknownNCT04910126Phase 2
- Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung CancerStatus unknownNCT04901754Phase 2
- Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid CarcinomaCompletedNCT04888429Phase 2